A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - Focus on magnetic resonance spectroscopy (MRS) studies

Human Psychopharmacology

Volumn 20, Issue 5, 2005, Pages 309-326

  Kim, Hyeonjin ^a   McGrath, Brent M ^b   Silverstone, Peter H ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anorexia nervosa; Anxiety; Bipolar disorder; Bulimia nervosa; Magnetic resonance spectroscopy; Major depressive disorder; Myo inositol; Obsessive compulsive disorder; Panic disorder; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR; INOSITOL; INOSITOL PHOSPHATE; LITHIUM; NEUROLEPTIC AGENT; PHOSPHATIDYLINOSITOL; PHOSPHORUS 32; PLACEBO; PROTON; SEROTONIN RECEPTOR; VALPROIC ACID;

ANOREXIA NERVOSA; ANXIETY DISORDER; BIOCHEMISTRY; BIPOLAR DISORDER; BULIMIA; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); EATING DISORDER; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; IN VIVO STUDY; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; TREATMENT FAILURE; TREATMENT OUTCOME;

BIPOLAR DISORDER; EATING DISORDERS; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PHOSPHATIDYLINOSITOLS; SCHIZOPHRENIA; SECOND MESSENGER SYSTEMS;

EID: 23244438118     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.693     Document Type: Review

References (152)

1. Allison JH, Blisner ME, Holland WH, Hipps PP, Sherman WR. 1976. Increased brain myo-inositol 1-phosphate in lithium-treated rats. Biochem Biophys Res Commun 71: 664-670.
2. Allison JH, Stewart MA. 1971. Reduces brain inositol in lithium-treated rats. Nat New Biol 233: 267-268.
3. Alvarez JC, Gluck N, Arnulf I, et al. 1999. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther 66: 617-624.
4. Alvin P, Zogheib J, Rey C, Losay J. 1993. Severe complications and mortality in mental eating disorders in adolescents. On 99 hospitalized patients. Arch Fr Pediatr 50: 755-762.
5. Antony MM, Downie F, Swinson RP. 1998. Diagnostic issues and epidemiology in obsessive-compulsive disorder. In Obsessive-Compulsive Disorder. Theory, Research, and Treatment, Swinson RP, Antony MM, Rachman S, Richter MA (eds). Guilford Press: New York; 3-32.
6. Aouizerate B, Guehl D, Cuny E, et al. 2004. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72: 195-221. Aouizerate B, Guehl D, Cuny E, et al. 2004. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72: 195-221.
7. Atack JR, Levine J, Belmaker RH. 1998. Cerebrospinal fluid inositol monophosphatase: elevated activity in depression and neuroleptic-treated schizophrenia. Biol Psychiatry 44: 433-437.
8. 0000 Atack JR. 2000. Lithium, phosphatidylinositol signaling, and bipolar disorder: the role of inositol monophosphatase. In Bipolar Medications - Mechanisms of Action, Manji HK, Bowden CL, Belmaker RH (eds). American Psychiatric Press: Washington; 1-30.
9. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. 2000. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47: 305-313.
10. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. 2001. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res 52: 87-99.
11. Bartha R, Stein MB, Williamson PC, et al. 1998. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry 155: 1584-1591.
12. Battaglia M, Ogliari A. 2005. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 29: 169-179.
13. Baxter LR, Schwartz JM, Mazziotta JC, et al. 1988. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 145: 1560-1563.
14. Benazon NR, Moore GJ, Rosenberg DR. 2003. Neurochemical analysis in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. J Am Acad Child Adolesc Psychiatry 42: 1279-1285.
15. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. 1995. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152: 1084-1086.
16. Benjamin J, Nemetz H, Fux M, Bleichman I, Agam G. 1997. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res 31: 489-495.
17. Berridge MJ. 1997. The 1996 Massry Prize. Inositol trisphosphate and calcium: two interacting second messengers. Am J Nephrol 17: 1-11.
18. Berridge MJ, Downes CP, Hanley MR. 1982. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206: 587-595.
19. Berridge MJ, Downes CP, Hanley MR. 1989. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59: 411-419.
20. Berridge MJ, Irvine RF. 1989. Inositol phosphates and cell signaling. Nature 341: 197-205.
21. Bersudsky Y, Einat H, Stahl Z, Belmaker RH. 1999. Epi-inositol and inositol depletion: two new treatment approaches in affective disorder. Curr Psychiatry Rep 1: 141-147.
22. Bhalla US, Iyengar R. 1999. Emergent properties of networks of biological signaling pathways. Science 283: 381-387.
23. Binesh N, Kumar A, Hwang S, Mintz J, Thomas MA. 2004. Neurochemistry of late-life major depression: a pilot two-dimensional MR spectroscopic study. J Magn Reson Med 20: 1039-1045.
24. Birchall J, Chappell J. 1988. Aluminum, chemical physiology, and Alzheimer's disease. Lancet 29: 1008-1010.
25. Block W, Bayer TA, Tepest R, et al. 2000. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett 289: 147-151.
26. 31P MRS of the schizophrenic brain in vivo. J Comput Assist Tomogr 23: 272.
27. Bootman MD, Berridge MJ, Roderick HL. 2002. Calcium signalling: more messengers, more channels, more complexity. Curr Biol 12: R563-R565.
28. Brambilla P, Stanley JA, Nicoletti M, et al. 2002. 1H MRS brain measures and acute lorazepam administration in healthy human subjects. Neuropsychopharmacology 26: 546-551.
29. Brambilla P, Stanley JA, Sassi RB, et al. 2004. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29: 1918-1924.
30. Brand A, Richter-Landsberg C, Leibfritz D. 1993. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289-298.
31. Breiter HC, Rauch SL, Kwong KK, et al. 1996. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 53: 595-606.
32. Bruhn H, Stoppe G, Staedt J, Merboldt KD, Hanicke W, Frahm J. 1993. Quantitative proton MRS in vivo shows cerebral myo-inositol and cholines to be unchanged in manic-depressive patients treated with lithium [Abstract]. Proceedings of the Society of Magnetic Resonance in Medicine, August 14-20, New York. 1543.
33. Cantarow A, Schepartz B. 1962. Biochemistry. W. B. Saunders Company: London; 216-218. Cantarow A, Schepartz B. 1962. Biochemistry. W. B. Saunders Company: London; 216-218.
34. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S. 2004. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. Metab Brain Dis 19: 125-134.
35. Cecil KM, DelBello MP, Morey R, Strakowski SM. 2002. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 4: 357-365. Cecil KM, DelBello MP, Morey R, Strakowski SM. 2002. Frontal lobe differences 0in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 4: 357-365.
36. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. 2003. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 53: 1059-1065.
37. Clark DM, Salkovskis PM, Breitholz E, et al. 1997. Misinterpretation of body sensations in panic disorder. J Consult Clin Psychol 65: 203-213.
38. Cohen H, Bar-haim N, Kotler M. 1996. Acute inositol induces anxiety in rats. Biol Psychiatry 40: 426-427.
39. Cohen H, Kotler M, Kaplan Z, Matar MA, Kofman O, Belmaker RH. 1997. Inositol has behavioral effects with adaptation after chronic administration. J Neural Transm 104: 299-305.
40. Colodny L, Hoffman RL. 1998. Inositol - clinical applications for exogenous use. Altern Med Review 3: 432-447.
41. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry, in press.
42. Dager SR, Friedman SD, Parow A, et al. 2004. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61: 450-458.
43. Davanzo P, Thomas MA, Yue K, et al. 2001. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24: 359-369.
44. Davanzo P, Yue K, Thomas MA, et al. 2003. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry 160: 1442-1452.
45. Deicken RF, Calabrese G, Merrin EL, et al. 1994. 31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry 36: 503-510.
46. Deicken RF, Fein G, Weiner MW. 1995a. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am J Psychiatry 152: 915-918.
47. Deicken RF, Weiner MW, Fein G. 1995b. Decreased temporal lobe phosphomonoesters in bipolar disorder. J Affect Disord 33: 195-199.
48. Delamillieure P, Constans JM, Fernandez J, Brazo P, Dollfus S. 2000. Proton magnetic resonance spectroscopy (1H-MRS) of the thalamus in schizophrenia. Eur Psychiatry 15: 489-491.
49. Delamillieure P, Constans JM, Fernandez J, et al. 2002. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr Bull 28: 329-339.
50. Di Costanzo A, Trojsi F, Tosetti M, et al. 2003. High-field proton MRS of human brain. Eur J Radiol 48: 146-153.
51. Doisy EA Jr. 1967. Inositol. In The Encyclopedia of Biochemistry, Williams RJ, Lansford EM Jr (eds). Reinhold Publishing Corporation: New York; 443.
52. Doyle A, Pollack MH. 2004. Long-term management of panic disorder. J Clin Psychiatry 65(Suppl. 5): 24-28.
53. Dwivedi Y, Janicak PG, Pandey GN. 1998. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology 138: 47-54.
54. Einat H, Belmaker RH. 2001. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord 62: 113-121.
55. Einat H, Belmaker RH, Kopilov M, Klein E, Gazawi H, Ben-Shachar D. 1999a. Rat brain monoamines after acute and chronic myo-inositol treatment. Eur Neuropsychopharmacol 10: 27-30.
56. Einat H, Belmaker RH, Zangen A, Overstreet DH, Yadid G. 2002. Chronic inositol treatment reduces depression-like immobility of Flinders Sensitive Line rats in the forced swim test. Depress Anxiety 15: 148-151.
57. Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M. 2001. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res 118: 77-83.
58. Einat H, Elkabaz-Shwortz Z, Cohen H, Kofman O, Belmaker RH. 1998. Chronic epi-inositol has an anxiolytic-like effect in the plus-maze model in rats. Int J Neuropsychopharmacol 1: 31-34.
59. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH. 1999b. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology 144: 158-162.
60. Elderkin-Thompson V, Thomas MA, Binesh N, et al. 2004. Brain metabolites and cognitive function among older depressed and healthy individuals using 2D MR spectroscopy. Neuropsychopharmacol 29: 2251-2257.
61. Fisher SK, Heacock AM, Agranoff BW. 1992. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 58: 18-38.
62. Frey R, Metzler D, Fischer P, et al. 1998. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 32: 411-420.
63. Friedman SD, Dager SR, Parow A, et al. 2004. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry 56: 340-348.
64. 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand 86: 455-462.
65. Fux M, Levine J, Aviv A, Belmaker RH. 1996. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 153: 1219-1221.
66. Fux M, Benjamin J, Belmaker RH. 1999. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmcol 2: 193-195.
67. Gelber D, Levine J, Belmaker RH. 2001. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord 29: 345-348.
68. Gould TD, Quiroz JA, Singh J, Zarate CA Jr, Manji HK. 2004. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry online: 1-22.
69. Grachev ID, Apkarian AV. 2000. Anxiety in healthy humans is associated with orbital frontal chemistry. Mol Psychiatry 5: 482-488.
70. Grachev ID, Fredrickson BE, Apkarian AV. 2002a. Brain chemistry reflects dual states of pain and anxiety in chronic low back pain. J Neural Transm 109: 1309-1334.
71. Grachev ID, Kumar R, Swarnkar A, Chang JK, Ramachandran TS. 2002b. Effect of posterior temporal-parietal hematoma on orbital frontal chemistry in relation to a cognitive and anxiety state: a combined 1H-MRS and neuropsychological study of an unusual case as compared with 16 healthy subjects. J Chem Neuroanat 23: 223-230.
72. Greil W, Steber R, van Calker D. 1991. The agonist-stimulated accumulation of inositol phosphates is attenuated in neutrophils from male patients under chronic lithium therapy. Biol Psychiatry 30: 443-451.
73. Gruber S, Frey R, Mlynarik V, et al. 2003a. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol 38: 403-408.
74. Gruber S, Mlynarik V, Moser E. 2003b. High-resolution 3D proton spectroscopic imaging of the human brain at 3 T: SNR issues and application for anatomy-matched voxel sizes. Magn Reson Med 49: 299-306.
75. Hamakawa H, Murashita J, Yamada N, Inubushi T, Kato N, Kato T. 2004. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci 58: 82-88.
76. 2 receptors but does not modify dexamphetamine-induced motor behavior: relevance to obsessive-compulsive disorder. Pharmacol Biochem Behav 68: 245-253.
77. Harvey BH, Brink CB, Seedat S, Stein DJ. 2002. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26: 21-32.
78. Hentschel J, Mockel R, Schlemmer HP, et al. 1999. 1H-MR spectroscopy in anorexia nervosa: the characteristic differences between patients and healthy subjects. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 170: 284-289.
79. Holub BJ. 1982. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease. Adv Nutr Res 4: 107-141.
80. Isaacks RE, Bender AS, Kim CY, Prieto NM, Norenberg MD. 1994. Osmotic regulation of myo-inositol uptake in primary astrocyte cultures. Neurochem Res 19: 331-338.
81. Jope RS, Song L, Grimes CA, et al. 1998. Selective increases in phosphoinositide signaling activity and G protein levels in post-mortem brain from subjects with schizophrenia or alcohol dependence. J Neurochem 70: 763-771.
82. Kaplan Z, Amir M, Swartz M, Levine J. 1996. Inositol treatment of post traumatic stress disorder. Anxiety 2: 51-52.
83. 31P-MRS. J Affect Disord 22: 185-190.
84. 7Li magnetic resonance spectroscopy. J Affect Disord 27: 53-60.
85. Kato T, Takahashi S, Shioiri T, Inubushi T. 1992. Brain phosphorus metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 26: 223-230.
86. Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. 1994a. Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder. Psychiatry Res 55: 41-50.
87. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. 1994b. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 31: 125-133.
88. Kato T, Shioiri T, Murashita J, et al. 1995. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med 25: 557-566.
89. Kato T, Inubushi T, Kato N. 1998. Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 10: 133-147.
90. 31P MRS study. Molecular Psychiatry 8: 316-323.
91. Kessler RC, McGonagle KA, Zhao S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
92. Kofman O, Agam G, Shapiro J, Spencer A. 1998. Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats. Psychopharmacology 139: 239-242.
93. Kofman O, Einat H, Cohen H, Tenne H, Shoshana C. 2000. The anxiolytic effect of chronic inositol depends on the baseline level of anxiety. J Neural Transm 107: 241-253.
94. Kumar A, Thomas A, Lavretsky H, et al. 2002. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry 159: 630-636.
95. Levine J. 1997. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7: 147-155.
96. Levine J, Barak Y, Gonzalves M, et al. 1995. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 152: 792-794.
97. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. 1999. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 45: 270-273.
98. Levine J, Umansky R, Ezrielev G, Belmaker RH. 1993. Lack of effect of inositol treatment in chronic schizophrenia. Biol Psychiatry 33: 673-675.
99. Li BSY, Regal J, Gonen O. 2001. SNR versus resolution in 3D 1H MRS of the human brain at high magnetic fields. Magn Reson Med 46: 1049-1053.
100. Lubrich B, Patishi Y, Kofman O, et al. 1997. Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol Psychiatry 2: 407-412.
101. Lubrich B, van Calker D. 1999. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21: 519-529.
102. Manji HK, Lenox RH. 2000. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48: 518-530.
103. Mikuni M, Kusumi I, Kagaya A, Kuroda Y, Mori H, Takahashi K. 1991. Increased 5-HT-2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolysis in platelets of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 15: 49-61.
104. Mockel R, Schlemmer HP, Guckel F, et al. 1999. 1H-MR spectroscopy in anorexia nervosa: reversible cerebral metabolic changes. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 170: 371-377.
105. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. 1997. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorus-31 magnetic resonance spectroscopy study. Am J Psychiatry 154: 116-118.
106. Moore CM, Breeze JL, Kukes TJ, et al. 1999. Effect of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 45: 1197-1202.
107. Moore CM, Breeze JL, Gruber SA, et al. 2000. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. Bipolar Disord 2: 207-216.
108. Mueser KT, McGurk SR. 2004. Schizophrenia. Lancet 363: 2063-2072.
109. Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. 2000. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy. Psychol Med. 30: 107-115.
110. Nemets B, Mishory A, Levine J, Belmaker RH. 1999. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm 106: 795-798.
111. Nemets B, Talesnick B, Belmaker RH, Levine J. 2002. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World J Biol Psychiatry 3: 147-149.
112. O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH. 2000. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 880: 84-91.
113. Ohrmann P, Kersting A, Suslow T, et al. 2004. Proton magnetic resonance spectroscopy in anorexia nervosa: correlations with cognition. NeuroReport 15: 549-553.
114. Palatnik A, Frolov K, Fux M, Benjamin J. 2001. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 21: 335-339.
115. Pandey GN, Ren X, Pandey SC, Dwivedi Y, Sharma R, Janicak PG. 2001. Hyperactive phosphoinositide signaling pathway in platelets of depressed patients: effect of desipramine treatment. Psychiatry Res 105: 23-32.
116. Patishi Y, Lubrich B, Berger M, Kofman O, van Calher D, Belmaker RH. 1996. Differential uptake of myo-inositol in vivo into rat brain areas. Eur Neuropsychopharmacol 6: 73-75.
117. Patrick L. 2002. Eating disorders: a review of the literature with emphasis on medical complications and clinical nutrition. Altern Med Rev 7: 184-202.
118. Petroff OA, Spencer DD, Alger JR. 1989. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 39: 1197-1202.
119. 31P NMR studies in schizophrenia. Biol Psychiatry 25: 14A-18A.
120. Pettegrew JW, Keshavan MS, Panchalingam K, et al. 1991. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-nave schizophrenics. Arch Gen Psychiatry 48: 563-568.
121. Pettegrew JW, Panchalingam K, Levine J, McClure RJ, Gershon S, Yao JK. 2001. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen. Biol Psychiatry 49: 444-453.
122. Phan KL, Fitzgerald DA, Cortese BM, Seraji-Bozorgzad N, Tancer ME, Moore GJ. 2005. Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. NeuroReport 16: 183-186.
123. Rauch SL, Jenike MA, Alpert NM, et al. 1994. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51: 62-70.
124. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. 2000. Decease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adoles Psychiatry 39: 1096-1103.
125. Rosenberg DR, Mirza Y, Russell A, et al. 2004. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43: 1146-1153.
126. Roser W, Bubl R, Buergin D, Seelig J, Radue EW, Rost B. 1999. Metabolic changes in the brain of patients with anorexia and bulimia nervosa as detected by proton magnetic resonance spectroscopy. Int J Eat Disord 26: 119-136.
127. 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 4: 59-63.
128. Rudnick A. 2002. The molecular turn in psychiatry: a philosophical analysis. J Med Phil 27: 287-296.
129. Seedat S, Stein DJ. 1999. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol 14: 353-356.
130. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. 1992. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 8: 43-49.
131. Sherman WR, Munsell LY, Gish BG, Honchar MP. 1985. Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis. J Neurochem 44: 798-807.
132. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. 1997. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 154: 1148-1150.
133. Shimon H, Sobolev Y, Davidson M, Haroutunian V, Belmaker RH, Agam G. 1998. Inositol levels are decreased in postmortem brain of schizophrenia patients. Biol Psychiatry 44: 428-432.
134. Shioiri T, Kato T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. 1996. High-energy phosphate metabolism in the frontal lobes of patients with panic disorder detected by phase-encoded 31P-MRS. Biol Psychiatry 40: 785-793.
135. Silverstone PH, McGrath BM, Kim H. 2005. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 7: 1-10.
136. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. 2002. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum Psychopharmacol Clin Exper 17: 321-327.
137. Skoog G, Skoog I. 1999. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 56: 121-127.
138. Spector R. 1998. Myo-inositol transport through the blood-brain barrier. Neurochem Res 13: 785-787.
139. Tarasow E, Panasiuk A, Siergiejczyk L, et al. 2003. MR and 1H MR spectroscopy of the brain in patients with liver cirrhosis and early stages of hepatic encephalopathy. Hepatogastroenterology 50: 2149-2153.
140. Thomas P. 2004. The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord 79: 3-8.
141. Thurston JH, Sherman WR, Hauhart RE, et al. 1989. Myo-inositol: a newly identified non-nitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res 26: 482-485.
142. Tupler LA, Davidson JRT, Smith RD, Lazeyras F, Charles HC, Krishnan KRR. 1997. A repeat proton magnetic resonance spectroscopy study in social phobia. Biol Psychiatry 42: 419-424.
143. Vaden DL, Ding D, Peterson B, Greenberg ML. 2001. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 276: 15466-15471.
144. Vandal R. 1997. Role of inositol in the treatment of psychiatric disorders. CNS Drugs 7: 6-16.
145. Videen JS, Michaelis T, Pinto P, Ross BD. 1995. Human cerebral osmolytes during chronic hyponatremia: a proton magnetic resonance spectroscopy study. J Clin Invest 95: 788-793.
146. 31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique-preliminary findings. Biol Psychiatry 41: 644-648.
147. Volz HP, Rzanny R, Riehemann S, et al. 1998. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 248: 289-295.
148. Williams RS, Cheng L, Mudge AW, Harwood AJ. 2002. A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
149. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. 1991. Localized phosphorus 31-magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 48: 578.
150. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. 2000. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 47: 475-481.
151. Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L. 2000. Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Res 855: 158-161.
152. Wyckoff N, Kumar A, Gupta RC, Alger J, Hwang S, Thomas MA. 2003. Magnetization transfer imaging and magnetic resonance spectroscopy of normal-appearing white matter in late-life major depression. J Magn Res Med 18: 537-543.